Botanix Pharmaceuticals : to present at ShareCafe - Hidden Gems Webinar

For personal use only

25 February 2022

Botanix to present at

ShareCafe Small Cap "Hidden Gems" Webinar

Philadelphia PA and Perth Australia, 25 February 2022: Clinical dermatology company, Botanix

Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, being held today, Friday 25th of February 2022.

The webinar will open with Botanix's presentation at 9:30am AWST (Perth) / 12:30pm AEDT (Sydney/Melbourne) with Executive Director, Matt Callahan providing an overview of its clinical pipeline, the significant potential for novel products in the dermatology sector and opportunities for adding new assets to the Botanix pipeline, as well as the upcoming clinical and operational milestones for 2022.

To view Botanix's presentation, please register here.

A copy of the investor presentation to be delivered during the webinar is attached.

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: [phone]	P: [phone]	P: [phone]
[e-mail]	[e-mail]	[e-mail]

For personal use only

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

ersonal use only

Investor Presentation

February 2022

Botanix Pharmaceuticals: a clinical stage dermatology company

Targeting billion-dollar markets with novel products

ersonal use only

Pharmaceutical focus

Topically driven

Significant markets

World-class team

Near-term catalysts

Developing novel treatments for common skin diseases (such as rosacea and acne), as well as life threatening bacterial infections

Dermatologists prefer creams and gels as first line treatment and our novel skin delivery technology (Permetrex™), provides a cosmetically elegant solution

Pipeline targets multi-billion dollar markets, with no new 'mechanism of action' products approved by FDA in decades for target indications in acne and rosacea

World-class and experienced team, with significant dermatology and antimicrobial drug track records as well as exits

Multiple upcoming catalysts including completion of Phase 1b/2 rosacea study, commencement Phase 2 antimicrobial study, canine AD data readout and new pipeline opportunities

2

www.botanixpharma.com

Pharmaceutical focus

Advanced late-stage pipeline

onlyBTX 1801 Antimicrobial

BTX 1702

Rosacea

useBTX 1503 Acne

BTX 1204A ersonalDermatitis

New indications Exploring opportunities

Ph 1	Ph 1b	Ph 2	Ph 3	Status
				Positive results announced,
				Phase 2b start end 1Q 2022
				Underway - enrolment
				complete by mid 2022
				Planning underway for Phase 3
				clinical studies
				Canine study well advanced -
				enrolment complete 1Q 2022
				Assessing new product
				opportunities for rapid clinical
				development or commercialisation
Dermatology	Antimicrobial	Dates are calendar years		3